other material
confidence high
sentiment positive
materiality 0.70
Editas reports EDIT-401 achieves ≥90% LDL-C reduction in NHPs; durable through 6 months
Editas Medicine, Inc.
- Single dose of EDIT-401 achieved ≥90% mean LDL-C reduction across all dose groups in non-human primates.
- Reduction durable through ~6 months; achieved with 10-40% functional editing of LDLR alleles and ≥6-fold hepatic LDLR protein increase.
- Promising preclinical safety profile: no adverse clinical observations at 1.5 mg/kg; undetectable oocyte delivery.
- Data in Ldlr loss-of-function mice suggest dose adjustments may not be needed for HeFH patients.
- Data support broader upregulation platform and continued advancement toward first-in-human clinical development.